{"id":"W4417342747","doi":"10.1182/blood.2025029210","title":"Asciminib demonstrates superior efficacy and safety in newly diagnosed chronic myeloid leukemia in the ASC4FIRST trial","year":2025,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Novartis Pharma; EUSA Pharma; Astellas Pharma; Incyte; Syndax Pharmaceuticals; BeiGene; Gilead Sciences; Celgene; Bristol-Myers Squibb; AstraZeneca; Amgen; Pfizer","keywords":"Discontinuation; Imatinib; Tolerability; Myeloid leukemia; Imatinib mesylate; Adverse effect; Hazard ratio; Clinical trial","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002153955,0.0006660059,0.0009476529,0.0001755736,0.0001951694,0.0008099724,0.000454107,0.0006110147,0.006239837],"category_scores_gemma":[0.001386261,0.0001573251,0.00113662,0.0002710024,0.0003565168,0.0005500378,0.0003228232,0.001618994,0.0006479035],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.000611718,"about_ca_system_score_gemma":0.0006953991,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0003949067,"about_ca_topic_score_gemma":0.001135926,"domain_scores_codex":[0.9994611,0.0003098612,0.00003691371,0.00005781524,0.00006456734,0.00006974029],"domain_scores_gemma":[0.9990281,0.0002086045,0.0003262875,0.00006434941,0.00008518061,0.0002874821],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.8511921,0.003724804,0.009301875,0.001934719,0.003267237,0.0002269964,0.0001565101,0.00196118,0.01128225,0.0006015704,0.01604785,0.100303],"study_design_scores_gemma":[0.7735373,0.1420827,0.05358954,0.0003314479,0.002914688,0.0007064969,0.00008077622,0.002898221,0.006287865,0.0008893332,0.0166128,0.00006875915],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9778176,0.009589038,0.0004105176,0.001641163,0.0003321475,0.000689245,0.002496709,0.0001270606,0.00689653],"genre_scores_gemma":[0.9904504,0.001865698,0.0006146075,0.0007366946,0.0003125524,0.000397233,0.003149688,0.00001808446,0.002455001],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.006239837,"threshold_uncertainty_score":0.02087432,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01240777381064919,"score_gpt":0.2700160286641859,"score_spread":0.2576082548535367,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}